Andrew D. Smith, MD, PhD, of the University of Mississippi Medical Center in Jackson, Mississippi, and colleagues presented data from their exploratory study yielding this finding at the annual meeting of the American Roentgen Ray Society (ARRS), held in Washington, DC, April 14-19, 2013. Describing metastatic melanoma survival as “devastatingly low” in their meeting abstract, the investigators noted that a predictive biomarker could be used to guide therapy, reduce unnecessary drug-related toxicity, and improve patient counseling. Read the story.